Matricelf News
26 articles
Middle Eastern Opportunities: Gencell And 2 More Promising Penny Stocks
GenCell Ltd., a company developing fuel cell-based energy systems, is navigating the penny stock market with a market cap of ₪30.41 million. Despite being unprofitable, the company maintains a strong financial position with no debt and short-term assets exceeding liabilities. GenCells strategic alliance for the EVOX system indicates potential growth in high-capacity power solutions for automotive logistics. However, the company faces financial sustainability concerns with a cash runway of less than a year. The article highlights the potential for growth in penny stocks, supported by solid financials, amidst rising oil prices and global market optimism.
Product StagePartners
Middle Eastern Penny Stocks To Watch In September 2025
HAYAH Insurance Company P.J.S.C., operating in the Middle East, offers health and life insurance solutions with a market cap of AED344 million. Despite being unprofitable, with a net loss of AED3.02 million for the first half of 2025, the company maintains financial stability through a debt-free status and a cash runway exceeding three years. The companys short-term assets surpass both its short- and long-term liabilities, providing some financial cushion amid volatility in share price. Managements experience offers potential for strategic navigation through current challenges.
מטריסלף מנצלת את הריצה של המניה בשוק ומגייסת 7 מיליון שקל
מטריסלף has raised approximately 7 million shekels at a price of 2.27 shekels per share with options at 3.39 shekels. This fundraising comes at an opportune time for the company, following a 150% increase in its stock price over the past month. The company is preparing for a significant milestone: transitioning to human trials after successful animal trials. In early August, the company reported successful preliminary results from a comprehensive safety trial in animals using engineered neural tissue for spinal cord injury treatment. Additional results related to this trial, which are a prerequisite for human proof-of-concept trials, are expected in the first quarter of 2026.
InvestmentProduct Stage
Middle Eastern Penny Stocks To Watch: 3 Picks With Market Caps Over US$10M
Duran Dogan Basim ve Ambalaj Sanayi A.S. is a packaging company operating across various international markets with a market cap of TRY2.13 billion. Despite generating TRY1.90 billion in revenue, the company remains unprofitable, though it has reduced losses by 13.4% annually over the past five years. The company has strong short-term asset coverage but carries a high net debt to equity ratio of 40.8%. Operating cash flow covers debt well, but the return on equity is negative at -10.68%. The boards average tenure of 11.3 years provides stability amidst these financial challenges.
Duran Dogan Basim ve Ambalaj Sanayi And 2 Middle Eastern Penny Stocks Making Waves
Duran Dogan Basim ve Ambalaj Sanayi A.S. operates in the packaging industry across various regions, including Turkey, Europe, and the Middle East. Despite a market cap of TRY1.54 billion, the company faces challenges typical of penny stocks, such as a negative return on equity and unprofitability. However, it has managed to reduce its losses by 13.4% annually over the past five years. The companys financial position is mixed, with short-term assets exceeding liabilities and debt being well covered by cash flow. Recent earnings show sales of TRY500.38 million but a net loss of TRY79.92 million, indicating ongoing efforts to stabilize financial performance amidst market volatility.
Discovering Opportunities: Duran Dogan Basim ve Ambalaj Sanayi And 2 Other Middle Eastern Penny Stocks
Duran Dogan Basim ve Ambalaj Sanayi A.S., a company specializing in packaging products, operates in Turkey and various international markets. Despite a market cap of TRY1.59 billion and a reduction in debt levels, the company faces financial challenges. It remains unprofitable, with declining sales and continued net losses, although these losses have narrowed slightly. The companys short-term assets cover both short and long-term liabilities, indicating strong liquidity, but high net debt to equity remains a concern. Additionally, the companys dividend is not well covered by earnings, suggesting potential sustainability issues. Overall, the financial health of Duran Dogan Basim ve Ambalaj Sanayi is a concern, impacting its growth prospects negatively.
Middle Eastern Penny Stocks With At Least US$10M Market Cap
Duran Dogan Basim ve Ambalaj Sanayi A.S., a company with a market cap of TRY1.62 billion, operates in the packaging and containers segment, generating TRY2 billion in revenue. Despite facing a net loss of TRY159.2 million, the company has improved its financial health by reducing its debt-to-equity ratio to 37.6% and maintaining satisfactory net debt levels. The firm covers both short- and long-term liabilities, indicating financial stability, although it struggles with high share price volatility and negative return on equity. The article highlights the companys financial challenges amidst broader market downturns affecting Gulf markets.
Middle Eastern Penny Stocks To Watch In April 2025
The article discusses the resilience of Middle Eastern stock markets, highlighting penny stocks as potential investment opportunities. Among the companies mentioned, Duran Dogan Basim ve Ambalaj Sanayi A.S. stands out in the packaging industry with a market cap of TRY1.87 billion. Despite reporting a net loss of TRY159.2 million for 2024, the company has improved its financial health by reducing its debt-to-equity ratio significantly over five years. The company has also reduced its losses annually by 26.2% and maintains experienced board leadership. However, the overall impact on the company is growth-negative due to its unprofitability.
Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments
Cellino and Matricelf have announced a collaboration to advance the biomanufacturing of personalized spinal cord injury treatments. Cellinos Nebula™ technology will be combined with Matricelfs regenerative approach to produce high-quality induced pluripotent stem cells (iPSCs) for scalable, patient-specific therapies. Cellino has successfully delivered autologous iPSC lines to Matricelf, which has transformed them into functional neural tissues. This collaboration aims to redefine treatment paradigms for spinal cord injury, with Matricelf planning to file an IND application next year to begin clinical trials. The partnership represents a significant step towards real-world applications of regenerative medicine.
Partners
Middle Eastern Penny Stocks With Market Caps Larger Than US$10M
Duran Dogan Basim ve Ambalaj Sanayi A.S. is highlighted as a notable Middle Eastern penny stock with a market capitalization of TRY1.73 billion and revenue of TRY1.37 billion from its Packaging & Containers segment. Despite being unprofitable with a negative Return on Equity, the company maintains stable short-term asset coverage over liabilities and satisfactory debt levels, with net debt to equity at 33.7%. The company has an established presence across multiple international markets, including Europe, the United States, the Middle East, Africa, and the Asia Pacific. The management team lacks sufficient tenure data, but the seasoned board provides stability amidst high share price volatility and reduced debt levels over recent years.
Matricelf is happy to share successful interim results of efficacy preclinical pilot study
The company is preparing for a clinical trial by demonstrating the efficacy of its treatment for spinal cord injury in an animal model. A preliminary efficacy study was conducted using immunodeficient rats to simulate human treatment. Interim results after 8 weeks showed a significant improvement in motor function for the treatment group compared to the control group. The treatment group had a 50% higher improvement rate in the BBB score and exhibited three times the strength of improvement in motor function. CEO Gil Hakim highlighted the companys commitment to developing innovative technology for spinal cord injury treatment, a condition with no current therapeutic solution. The positive interim results are a promising step towards starting the clinical trial.
מטריסלף נוסקת ב-23% בעקבות הצלחה בייצור שתל רקמה עצבית אנושית
מטריסלף, a biotechnology company specializing in tissue engineering, has successfully produced human tissue implants for the treatment of spinal cord injuries. The company plans to begin animal testing in the coming weeks and has recently signed an agreement with a pharmaceutical company for knowledge transfer. The news has resulted in a 23% increase in מטריסלףs stock. The article also mentions weak labor market conditions and declining wages in the high-tech sector.
Expand
Israeli biotech co Matricelf ranked 3rd in Startups World Cup
Israeli biotechnology company Matricelf has ranked third in the 2022 Startups World Cup. The company aims to develop autologous implants for the regeneration of damaged body tissues and organs, with a focus on spinal cord injuries. Matricelfs technology uses a patented process that combines a temperature-sensitive hydrogel, patient-derived omentum tissue, and pluripotent stem cells. The companys success in the competition represents recognition of its innovative approach and potential impact in the field of regenerative medicine. Matricelf was founded in 2019 and is based on technology developed in Prof. Tal Dvirs laboratory at Tel Aviv University.
InvestmentExpand
Matricelf has reached a major milestone
Matricelf has successfully produced in-house induced pluripotent stem cells (iPSCs) from human peripheral blood cells. The companys reprogramming of cells to iPSCs allows for the differentiation into different cell types, including neural cells. Matricelf is developing 3D autologous implants for the regeneration of damaged tissues, using a proprietary technology that combines a thermo-responsive hydrogel and iPSCs generated from the patients peripheral blood. The ability to independently produce iPSCs positions Matricelf as a central player in the cellular therapy and regenerative medicine industry. The company sees this as a significant economic opportunity in the market dealing with spinal cord injury and other medical conditions. Matricelf is an Israeli biotechnology company founded in 2019 and is based in Ness Ziona, Israel.
Expand
Matricelf teams with TAU on 3D organ printing
Israeli regenerative medicine company Matricelf Ltd. has signed an exclusive global licensing agreement with Tel Aviv Universitys technology transfer company Ramot for the commercialization of a 3D bioprinting technology for organs and tissues. The technology, developed by Prof. Tal Dvir, allows for the simultaneous 3D printing of cells and extracellular matrix (ECM) to produce scaled-up living human tissues and organs. Matricelf will have the global rights and exclusivity to develop and produce the technology, subject to meeting milestones. The company aims to sign at least one commercialization agreement with a third party within 36 months. The technology has the potential to revolutionize the regenerative medicine sector and address the growing shortage of organs for transplants.
Partners
Matricelf treats pig's spinal cord injury with human implants
Israeli biotech company Matricelf has successfully completed a usability trial with human implants for replacing the injured spinal cord of a living pig. The company is developing autologous implants for the regeneration of damaged tissues using stem cells from the patients themselves. The trial simulated the anticipated surgical procedure in humans and was completed with major success. Matricelf sees this milestone as a significant achievement and a step towards future trials in animals and humans. The company was founded in 2019 and has been traded on the Tel Aviv Stock Exchange since June 2021. Matricelf has developed its implants using a unique technology that combines a thermo-responsive hydrogel and pluripotent stem cells. The company has 10 employees and has raised NIS 24 million to date.
InvestmentExpand
חברת המו"פ מטריסלף מקבלת אישור להתקדמות פיתוח המוצר המרכזי
Medical technology company מטריסלף has received approval from the Helsinki Committee for human trials at the Medical Center in Herzliya. The company develops autologous implants for tissue repair using the patients own cells and extracellular components. The implants are made using a unique process that combines processed fat tissue and mature stem cells taken from the patient. The companys stock market value has increased by over 100% since its listing on the Tel Aviv Stock Exchange in June, reaching a value of 177 million NIS. The company reported a loss of 9.4 million NIS in the second quarter of the year.
InvestmentExpand
מטריסלף השלימה בהצלחה ניסוי לייצור שתל נוירונלי אנושי
Medical technology company מטריסלף has successfully completed a trial to produce a human neuronal implant. The company used its development technology to create three-dimensional implants made of human hydrogel, which contain pluripotent stem cells that differentiate into human neuronal tissue. The company identified the morphology and markers of nerve cells that make up the implant. The nerve implants are single millimeters in size, and multiple implants will be transplanted in humans as part of future treatment. The nerve implant is intended for the treatment of individuals with traumatic spinal cord injuries. מטריסלף is also developing autologous implants for tissue regeneration using a unique technology that combines temperature-sensitive hydrogel and adipose tissue. The company prepares the implants by processing a piece of the patients own adipose tissue and mature pluripotent stem cells taken from the patient.
CustomersInvestment
חברת הביוטכנולוגיה מטריסלף מצטרפת לבורסה בתל-אביב
מטריסלף, a regenerative medicine and tissue engineering company, has successfully completed its initial public offering (IPO). The company has developed a technological platform for tissue engineering that allows the production of various types of human tissue sourced from the patient (autologous transplant). The IPO raised 24 million NIS in gross proceeds, with a post-IPO valuation of approximately 70 million NIS. The company focuses on developing autologous implants for the reconstruction of damaged tissues using cellular and extracellular components. The technology was developed in the laboratory of Prof. Tal Dvir at Tel Aviv University. MatrixLife plans to use the funds to accelerate its research and development activities and move towards a Phase I/IIa clinical safety trial for the treatment of spinal cord injury.
InvestmentPublic TradingExpand
חברה העוסקת בפיתוח איברים מלאכותיים מבקשת להנפיק בת"א
Matricelf, a biotechnology company specializing in the development of artificial organs that combine biological and artificial tissue, is planning to go public on the Tel Aviv Stock Exchange. The company, founded in 2019, is still in the early stages of its operations. In November 2020, the company raised funds at a value of $8 million. The company aims to raise close to $11 million before the money, which will bring the company, according to the plan, until the end of the animal trials stage at the end of 2023.
Public TradingInvestment
Matricelf, the maker of 3D printed heart, named regional winner of the Startup World Cup
Matricelf, a personalized platform for autologous regenerative medicine, has been declared the local winner of the Startup World Cup. The company has developed a platform for 3D printouts of otological implants and is also working on motor implants for spinal cord injuries. Matricelf aims to represent Israel in the global competition and bring hope to disabled patients. The second and third place winners are i-BrainTech and Hargol FoodTech. The winner of the global competition will receive a $1 million investment from Pegasus Tech Ventures.
Expand
Israeli biotech company Matricelf wins Calcalist's StartUp+ competition
Matricelf, an Israeli biotechnology company active in tissue engineering, won first place in the StartUp+ competition. They received a grant, office space, and other prizes. Genetika+ took second place. The competition aimed to support young startups in a challenging financial time. Matricelf has developed a platform for 3D printing tissues and organs, while Genetika+ focuses on personalized technology for digital health. Matricelfs main partner is Bayer. The article also mentions three other companies that reached the finals: Suridata.ai, Lynx.MD, and Appwrite.
CustomersPartners
המנצחת בתחרות +StartUp: חברת הביוטכנולוגיה מטריסלף
Israeli biotech start-up Matricelf, which is developing a platform for the 3D printing of tissues and organs, has won a competition organised by Calcalist and Poalim Hi-Tech. The company will receive a range of prizes, including a cash grant of ILS 40,000 ($12,000), eight months of office rental at the Mixer workspace, digital advertising in Calcalist, and guidance and advice from Poalim Hi-Tech. Matricelfs main partner is pharmaceutical giant Bayer, which will test new drugs on human heart tissues printed in 3D in the laboratory of Prof. Tal Dvir.
InvestmentPartnersCustomers
Bayer, Tel Aviv University test drugs on 3D-printed hearts
Tel Aviv Universitys Laboratory for Tissue Engineering and Regenerative Medicine has entered into a collaboration agreement with pharmaceutical giant Bayer to use 3D-printed human heart tissues for testing the cardiotoxicity of experimental drugs. The collaboration will enable Bayer to expand its open innovation activities to Israels dynamic ecosystem for innovation in biotech and medical research. The 3D-printed tissues have the potential to revolutionize drug screening by providing a more accurate representation of real heart tissues. Tel Aviv University hopes to eventually offer the ability to do pre-clinical trials on complete printed organs. The technology has been licensed to a spin-off company called Matricelf, which focuses on engineering personalized spinal-cord implants.
Partners
SEED AWARD Moves Matricelf One Step Closer to Creating World's First 3D Printed Human Heart
Israeli scientists unveil world's first 3D-printed heart with human tissue
Scientists at Tel Aviv University have successfully 3D printed a heart with human tissue and vessels, marking a major medical breakthrough. The heart, about the size of a rabbits, is the first to be engineered and printed with cells and blood vessels. While there are still challenges to overcome, such as teaching the printed hearts to function like real ones, the researchers hope to transplant them into animal models within a year. The ultimate goal is to produce fully working 3D printed hearts for human transplants. This development has the potential to revolutionize the field of organ transplantation and address the limited availability of donors.
Customers
